# Sermorelin References: The GHRH(1-29) Studies Cited in This Digest

> Sermorelin references — the full citation list behind this GHRH(1-29) digest, with DOIs and PubMed links to every study referenced across the site.

The full reference list, with DOIs and PubMed links you can check yourself.

## How to read this list

Every numbered citation marker across this site — [1], [2], and so on — points to an entry below. Each entry carries the authors, journal, year, and a DOI or PubMed link so you can read the source yourself. Findings from the closely related analog **tesamorelin** are labeled as such wherever they appear, so the sermorelin record stays distinct from its cousin's. This is a reading list, not a clinical protocol.

## References

[1] Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. 1996;81(3):1189-96. https://pubmed.ncbi.nlm.nih.gov/8772599/
[2] Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/
[3] Wilton P, Chardet Y, Danielson K, Widlund L, Gunnarsson R. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. https://pubmed.ncbi.nlm.nih.gov/8329825/
[4] Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/
[5] Blackman MR. Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time. Ann Intern Med. 2008;149(9):677-9. https://pubmed.ncbi.nlm.nih.gov/18981489/
[6] Granata R, Leone S, Zhang X, Gesmundo I, Steenblock C, Cai R, Sha W, Ghigo E, Hare JM, Bornstein SR, Schally AV. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[7] Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/
[8] Bowers CY, Granda-Ayala R. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine. 2001;14:79-86. https://pubmed.ncbi.nlm.nih.gov/11322505/
[9] Sáez JM. Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment. Endocr Metab Immune Disord Drug Targets. 2012;12:274-86. https://pubmed.ncbi.nlm.nih.gov/22524398/
[10] Quik EH, Valk GD, et al. Reduced growth hormone secretion after cranial irradiation contributes to neurocognitive dysfunction. Growth Horm IGF Res. 2012;22:42-7. https://pubmed.ncbi.nlm.nih.gov/22269954/
[11] Massoud AF, et al. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin. J Clin Endocrinol Metab. 1991;72(2):492-499. https://pubmed.ncbi.nlm.nih.gov/1671389/
[12] Pedrolli F, Morello G, et al. Growth hormone-releasing hormone attenuates amyloid deposition and neuroinflammation in Alzheimer's disease models. Cell Death Dis. 2026. https://pubmed.ncbi.nlm.nih.gov/41946684/
[13] Villar-Gouy KR, Salmon CEG, et al. Brain morphometry and estimation of aging brain in subjects with congenital untreated isolated GH deficiency. J Endocrinol Invest. 2024. https://pubmed.ncbi.nlm.nih.gov/38627331/
[14] Gahete MD, et al. Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond. Rev Endocr Metab Disord. 2025. https://pubmed.ncbi.nlm.nih.gov/39579280/

---

A kitchen-table reading of the sermorelin record — every GHRH(1-29) figure explained in plain words and tied to the study that measured it, the body-composition data kept where it belongs as tesamorelin, and the spot where the long-term adult anti-aging evidence simply runs out left honestly empty; despite the 'shop' in the name there is no clinic, no vendor, and nothing here is dosed, dispensed, or sold.